Tarbox Family Office’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-16
Closed -$1K 1157
2021
Q4
$1K Buy
+16
New +$1.24K ﹤0.01% 1078

Other funds holding ZNTL

Tarbox Family Office's ZNTL Position: Q1 2022 in Review

Tarbox Family Office sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2022, closing a stake of 16 shares — an estimated $1K sold.

Tarbox Family Office first reported a position in ZNTL in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 128 funds tracked by Wall St. Rank hold ZNTL as of Q1 2022.

  • Tarbox Family Office reported no remaining Zentalis Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Tarbox Family Office sold 16 Zentalis Pharmaceuticals shares in Q1 2022, an estimated $1K.
  • Tarbox Family Office first reported a position in Zentalis Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Tarbox Family Office's Zentalis Pharmaceuticals position peaked at $1K in Q4 2021.
  • 128 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2022.

Based on Tarbox Family Office's 13F filing for Q1 2022, filed 25 Apr 2022.